Previous 10 | Next 10 |
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start off another busy day of trading with the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com New test flights, an uplisting, and a failed merger are just some of ...
Arcus Biosciences Set to Join S&P SmallCap 600 Arcus Biosciences Set to Join S&P SmallCap 600 PR Newswire NEW YORK , April 4, 2022 /PRNewswire/ -- Arcus Biosciences Inc. (NYSE:RCUS) will replace Investors Bancorp Inc. (NASD:ISBC) in the S&...
Arcus Biosciences (NYSE:RCUS) has jumped 9.7% postmarket on the news it's set to join the S&P SmallCap 600 index. It's moving in to replace Investors Bancorp (ISBC), set to be acquired by Citizens Financial Group in a deal closing soon. The index change is effective prior to the open of t...
Initial pharmacokinetic (PK)/pharmacodynamic (PD) data for AB521, Arcus’s HIF-2a inhibitor, in healthy volunteers confirm its potential to have an improved clinical profile compared to that of the only approved HIF-2a inhibitor; data were presented at ESMO Targeted Anticancer...
Arcus Biosciences press release (NYSE:RCUS): Q4 GAAP EPS of $3.71 beats by $4.33. Revenue of $354.5M (+3635.5% Y/Y) beats by $305.07M. “Arcus is starting 2022 with a strong cash position and late-stage pipeline that includes two ongoing, and soon to be four, registrational Phase 3 stud...
Presentations of randomized data for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer (NSCLC; ARC-7) and quemliclustat in pancreatic cancer (ARC-8) are planned for 2H:22 Initial pharmacokinetic (PK)/pharmacodynamic (PD) data for AB521, Arcus’s...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributor Brian Orelli analyzes Gilead 's (NASDAQ: GILD) earnings report and discusses why the biotech giant could see fairly low revenue growth or even see earnings dr...
Arcus Biosciences, Inc. (NYSE: RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that management will participate at the following upcoming investor conferences: SVB ...
Despite beating Street estimates on revenue and non-GAAP EPS, Gilead Sciences (NASDAQ:GILD) shares are down ~4% in after-hours trading. However, Q4 2021 revenue of $7.2B was a 2% decrease compared to the same period in 2021. Gilead attributed the drop to a decline in sales of its CO...
Six clinical-stage molecules targeting TIGIT, the adenosine axis (CD73 and dual A2a/A2b), HIF-2a and PD-1 continue to advance Multiple datasets are expected in 2022, including presentations planned for domvanalimab and etrumadenant in 1L PD-L1 high non-small cell lung cancer...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...